The immediate and powerful effects of THC are explained because of the special affinity it has with the CB1 type receptors, which mediate crucial processes in the brain. The less prominent (but no less important) action of CBD was explained, at least for a while, by hypothesizing that it binds to CB2 type receptors, hence its more diffuse manner of exercising changes in the body. Early on, the antipsychotic effects of cannabidiol were observed, an aspect which seemed to be in consonance with this initial hypothesis.
A group of specialists at the National Cancer Institute reviewed some experiments rhesus monkeys and rodents whose results implied that CBD has the capacity to inhibit the division of cancerous cells (especially in types of leukemia and lymphoma), to lower the probability of affected tissue to spread to neighboring tissues, and to increase the effectiveness of macrophage cells to attack cancerous cells.
While CBD and marijuana have been used for centuries for many remedies, the role CBD can play in lessening the severity and number of seizures in those diagnosed with epilepsy came into the spotlight in the early 2000’s. That’s when the Figi family began looking for a way to treat their daughter Charlotte’s seizures. At the time, she was suffering upwards of 300 seizures per week. (8)
That leaves those touting CBD’s effectiveness pointing primarily to research in mice and petri dishes. There, CBD (sometimes combined with small amounts of THC) has shown promise for helping pain, neurological conditions like anxiety and PTSD, and the immune system—and therefore potentially arthritis, diabetes, multiple sclerosis, cancer, and more.
Furthermore, this number is expected to grow. According to the CDC, it is estimated that by 2040, over 78 million adults will have arthritis that has been diagnosed by a doctor, with 43% of those individuals limited in terms of activity because of the disease, without taking into effect other conditions that contribute to arthritis side effects, like growing obesity numbers and more.
More recent experiments, involving the administration of a part CBD part THC solution, have yielded results that contradict the first supposition. At present, on the evidence that cannabidiol reduces some of the psychoactive effects of tetrahydrocannabinol (acting as a de facto antidepressant), scientists argue that cannabidiol has a holistic but indirect influence on all cannabinoid receptors in the endocannabinoid system. The main consequence of this impact seems to be an increase in the production of endocannabinoids. This is now the prevailing idea that accounts for the mountains of empirical evidence of how the benefits of cannabidiol are expressed at the cellular level.